

# 1 **Dynamics of neurotransmitter and extracellular vesicle-derived microRNA** 2 **landscapes during heroin and methamphetamine withdrawal**

3  
4 **Juehua Yu<sup>1,2,#,\*</sup>, Fengrong Chen<sup>1,2,#</sup>, Yu Xu<sup>1,3,#</sup>, Kai Shi<sup>4</sup>, Zunyue Zhang<sup>1,2</sup>, Qingyan Peng<sup>1,2</sup>,**  
5 **Zhenrong Xie<sup>1,2</sup>, Jing Lu<sup>1,5</sup>, Hongjin Wu<sup>1,2</sup>, Yuru Ma<sup>1,2</sup>, Lei Zou<sup>1,2</sup>, Yong Zhou<sup>1,2</sup>, Cheng**  
6 **Chen<sup>1,2,3</sup>, Jiqing Yang<sup>1,2</sup>, Yiqun Kuang<sup>1,2</sup>, Yuan Wang<sup>6</sup>, Tao Tan<sup>7</sup>, Mei Zhu<sup>1</sup>, Trevor W.**  
7 **Robbins<sup>8,9</sup>, Kunhua Wang<sup>1,2,3,\*</sup>**

8  
9 <sup>1</sup>NHC Key Laboratory of Drug Addiction Medicine (Kunming Medical University), First Affiliated  
10 Hospital of Kunming Medical University, Kunming, Yunnan 650032, China. <sup>2</sup>Centre for  
11 Experimental Studies and Research, First Affiliated Hospital of Kunming Medical University,  
12 Kunming, Yunnan 650032, China. <sup>3</sup>Yunnan Institute of Digestive Disease, First Affiliated Hospital of  
13 Kunming Medical University, Kunming, Yunnan 650032, China. <sup>4</sup>College of Science, Guilin  
14 University of Technology, Guilin 541004, China. <sup>5</sup>Department of Psychiatry, First Affiliated Hospital  
15 of Kunming Medical University, Kunming, Yunnan 650032, China. <sup>6</sup>Department of R&D, Echo  
16 Biotech Co., Ltd, Beijing, China. <sup>7</sup>Institute of Primate Translational Medicine, Kunming University of  
17 Science and Technology, Kunming, Yunnan 650500, China. <sup>8</sup>Department of Psychology and the  
18 Behavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge, United  
19 Kingdom. <sup>9</sup>Institute of Science and Technology for Brain-Inspired Intelligence, Fudan University,  
20 Shanghai, China.

21  
22 **\*Correspondence: Juehua Yu, PhD; Email: [juehuayu@gmail.com](mailto:juehuayu@gmail.com) Kunhua Wang, MD; Email:**  
23 **[kunhuawang1@163.com](mailto:kunhuawang1@163.com)** NHC Key Laboratory of Drug Addiction Medicine (Kunming Medical  
24 University), The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650032,  
25 China.

26 **Authorship notes:** JY, FC, and YX contributed equally to this work. JY and KW contributed equally  
27 to this work.

28 **Conflicts of interest:** The authors declare that there are no conflicts of interest.

29

30 **Abstract**

31 Circulating miRNAs in small vesicles known as exosomes within blood have been emerging as a new  
32 research hotspot in the field of psychiatric disorders. The aim of this work was to characterize the changes  
33 in exosomal microRNA profiles, both short-term and long-term, during substance withdrawal using a  
34 cross-sectional study design. Using weighted gene co-expression network analysis, a series of known,  
35 conserved, and novel exosomal microRNAs were identified as being associated with withdrawal stage and  
36 key neurotransmitters GABA, choline, and serotonin. Bioinformatics analyses established that the  
37 differences in the miRNA profile target signaling pathways are associated with developmental and  
38 intellectual abnormalities. Notably, a set of dysregulated microRNA signatures including hsa-miR-451a  
39 and hsa-mir-21a resulted in an AUC of 0.966 and 0.861, respectively, for predicting patients with  
40 substance use disorders. Furthermore, hsa-miR-744a-5p was positively correlated with serotonin, and its  
41 important role in maintaining neuronal development and function was revealed using an *in vitro* human  
42 induced pluripotent stem cells derived neuronal model. Taken together, these data suggest that the  
43 microRNA content of circulating exosomes represent a biomolecular “fingerprint” of the progression of  
44 substance withdrawal and may uncover the putative mechanism of how these exosomal microRNAs  
45 contribute to central nervous system development and function.

46

47

48 **Keywords:** substance use disorders, withdrawal, neurotransmitter, exosomes, microRNA, induced  
49 pluripotent stem cells, neurite outgrowth

## 50 **Introduction**

51 According to various estimates, between 35 and 50 million people worldwide suffer from severe substance  
52 use disorders (SUDs). These are associated with serious health problems and harmful consequences,  
53 including mortality, morbidity, and criminality (Brady, 2019; Lehmann & Fingerhood, 2018). The use of  
54 heroin and methamphetamine, the two most commonly abused illegal substances in China, account for  
55 approximately 37% and 56.1% of registered drug abusers, respectively (The State Council China, 2019).  
56 Both heroin and methamphetamine dependence are chronic, often relapsing brain disorders that cause  
57 acute and protracted withdrawal symptoms when their use is discontinued or reduced. For some  
58 individuals, severe psychological withdrawal symptoms such as depression, anxiety, reduced motivation,  
59 difficulties experiencing pleasure, and apathy can last for weeks, months, or even years. These symptoms  
60 may lead patients to seek relief by returning to substance use, resulting in a pattern of repeated relapse  
61 (Bell & Strang, 2020; Cruickshank & Dyer, 2009).

62 In this complex group of disorders which have a multitude of signs and symptoms associated with  
63 both nervous system and other body systems, the dysfunctioning of neurotransmitter systems has been  
64 proposed to play a significant role in the development of substance dependence (Duman *et al*, 2019;  
65 Muller & Homberg, 2015; Tomkins & Sellers, 2001). Increased platelet serotonin was first reported in a  
66 small sample of opiate addicts compared with alcoholics and control participants (Schmidt *et al*, 1997).  
67 Conversely, a significant increase in plasma dopamine but not platelet serotonin has been shown in heroin  
68 and cocaine addicts (Macedo *et al*, 1998). Stimulant abuse (e.g., methamphetamine) is associated with  
69 elevated immune activation and lower tryptophan (Carrico *et al*, 2008), in line with the finding that  
70 decreased serum tryptophan, a precursor of serotonin, has been found in heroin treated rats (Zheng *et al*,  
71 2013).

72 Cumulating structural and functional brain changes, as well as neurocognitive deficits and  
73 emotional impairments in both heroin and methamphetamine dependent populations have been  
74 demonstrated in neuropsychological studies. For example, a general loss of neurons and astrocytes  
75 (Buttner & Weis, 2006), a decreased number of neural precursor cells, accompanied by lower rates of  
76 proliferation (Bayer *et al*, 2015), and a marked loss of dendritic trees in targeting cells (Oehmichen *et al*,  
77 1996) have been found in the *post mortem* brains of heroin and methamphetamine addicts. These findings  
78 suggest that prolonged substance use significantly impacts neurogenesis and the way the brain works by  
79 changing the way nerve cells communicate with one another. In animal models, chronic administration of  
80 illegal abused substances results in alterations to synaptic plasticity and neuronal apoptosis in the nucleus  
81 accumbens, ventral tegmental area, and hippocampus (Kourrich *et al*, 2015; Pignatelli & Bonci, 2015).  
82 However, whether the degenerative processes with adverse effects on neurodevelopmental and  
83 neuropsychiatric functions associated with substance dependence can be discontinued or reversed through  
84 the elimination of addictive substances remains questionable (Norman *et al*, 2009). Only limited molecular  
85 biomarkers have been associated with withdrawal symptoms and the mechanisms underlying altered  
86 communications between the peripheral circulation and the central nervous system (CNS) that impact

87 neurodevelopmental and neuropsychiatric functions in the context of SUDs are not fully understood  
88 (Downey & Loftis, 2014).

89 Exosomes are small endosomal derived membrane microvesicles (40–140 nm in diameter) present  
90 in a variety of biofluids such as saliva, urine, and plasma, and they have a significant role in a series of  
91 fundamental biological processes including cellular activity regulation, intercellular communication, and  
92 the capacity to allow cells to exchange proteins, lipids, and genetic materials (Chen *et al*, 2019b; Huang *et*  
93 *al*, 2018; Zhang *et al*, 2018). The contents of exosomes are stable and the value of analyzing enriched  
94 exosomal DNA/RNA is greater than that of non-exosomal DNA/RNA, as the nucleotide sequence  
95 information is essentially diluted in the peripheral circulating blood that usually results in an increased  
96 signal-to-noise ratio (Cheng *et al*, 2015; Ramirez *et al*, 2018). As one of the most important contents in  
97 exosomes, miRNA are non-coding RNA species that can bind to complementary sites of the 3'  
98 untranslated region of their mRNA targets resulting in the downregulation of gene expression. Notably,  
99 exosomes can migrate across the blood-brain barrier (BBB) (Chen *et al*, 2016; Saeedi *et al*, 2019) and their  
100 contents can be released into the extracellular environment by binding to RNA-binding proteins or through  
101 secretion in cell-derived plasma microvesicles. As a result, dysregulated exosomal miRNA expression  
102 profiling in peripheral circulation may therefore reflect physiological state and have diagnostic potential  
103 for neurological and neuropsychiatric disorders. For example, a novel 16-miRNA signature has been  
104 identified and including established risk factors (e.g., age, sex, and apolipoprotein  $\epsilon$ 4 allele status) to a  
105 panel of dysregulated exosomal miRNA would result in a sensitivity and specificity of 87% and 77%,  
106 respectively, for predicting Alzheimer's disease (Cheng *et al*, 2015). In addition, studies have shown that  
107 exosomes are involved in the transmission and release of  $\alpha$ -synuclein, which are correlated with the  
108 severity of cognitive impairment in patients with Parkinson's disease and dementia (Stuendl *et al*, 2016).  
109 Therefore, investigating exosomes may identify valuable biomarkers with diagnostic potential and offer  
110 the opportunity to uncover the regulatory role of peripheral circulating exosomes in substance dependence  
111 and withdrawal.

112 Although high-throughput sequencing has been attempted to explore the miRNA content in  
113 exosomes from patients with SUDs (Chen *et al*, 2021; Wang *et al*, 2019), the underlying molecular  
114 mechanisms of exosomal miRNAs in the regulation of withdrawal symptoms remains to be fully  
115 elucidated. In the present study, we aimed to profile neurotransmitter and exosomal miRNAs in plasma to  
116 identify a subset of neurotransmitter and exosomal miRNA biomarkers in a large group of patients with  
117 SUDs undergoing withdrawal. We subsequently explored the molecular function and possible mechanism  
118 of identified signature miRNA using an *in vitro* model of human induced pluripotent stem cells (iPSCs)  
119 derived neurons. Taken together, the analyses of neurotransmitter and miRNA content in peripheral  
120 circulating exosomes may strengthen our knowledge and provide valuable information contributing to the  
121 development of diagnosis and therapeutic interventions, and a mechanistic view of disease phenotypes  
122 during substance dependence and withdrawal.

123

124 **Materials and Methods**

## 125 *Ethics statement and clinical sample collection*

126 In this cross-sectional study, a total of 120 male patients with SUDs were recruited from a joint program  
127 for drug detoxification and rehabilitation in the First Affiliated Hospital of Kunming Medical University  
128 and the Kunming Drug Rehabilitation Center from January 2018 to October 2019. Twenty age-matched  
129 healthy male volunteers were recruited from the Physical Examination Center in the First Affiliated  
130 Hospital of Kunming Medical University. Prior to inclusion in the study, general demographic data and  
131 complete medical, psychiatric, and substance abuse histories for all participants were collected for all  
132 participants. Written informed consent for participation was provided by all individuals. The study was  
133 approved by the First Affiliated Hospital of Kunming Medical University Ethics Committee (2018-L-42).  
134 Each patient was diagnosed as having opioid (e.g., heroin) or amphetamine (e.g., methamphetamine)  
135 dependence based on the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5)  
136 criteria provided by the American Psychiatric Association. Individuals were excluded if they fulfilled any  
137 of the following conditions: any other DSM-5 axis I or II disorders (other than amphetamine/opioid  
138 dependence); HIV antibodies; neurological disorders or serious medical conditions; polysubstance use. Of  
139 the total 140 participants recruited, there were 60 heroin-dependent patients (HDPs, 20:20:20 at the 7-day,  
140 3-month, and 12-month withdrawal stage), 60 methamphetamine-dependent patients (MDPs, 20:20:20 at  
141 the 7-day, 3-month, and 12-month withdrawal stage), and 20 healthy controls (HCs). An initial 10  
142 participants per each group were used as the discovery cohort, and the subsequent 10 participants per each  
143 group were used as the validation cohort (**Figure 1A**). Peripheral blood samples were collected in 5 ml  
144 EDTA□2Na vacuum tubes between 8:00 and 10:00 AM in order to minimize a possible rhythm variance  
145 bias and the clinical data were obtained at the same time. Within 1 hour of blood collection, plasma was  
146 separated out by centrifugation and was immediately aliquoted and frozen in liquid nitrogen. The stored  
147 plasma samples were transported and packaged on dry ice.

148

## 149 *Scales*

150 The Hamilton-Anxiety scale (HAM-A) is a semi-structured questionnaire administered by the interviewer,  
151 who assesses 14 clusters of questions, each concerning a series of symptoms. Seven elements examine  
152 psychological stress and seven examine physical stress with a satisfactory inter-rater reliability (Hamilton,  
153 1959). The Hamilton-Depression Scale (HAM-D) is a semi-structured questionnaire administered by the  
154 interviewer, who assesses 21 clusters of questions, measuring depression symptoms (Hamilton, 1960).

155

## 156 *Sample preparation and instrumentation*

157 Samples were thawed on ice-bath and 25 µl of each plasma sample was transferred to a 96-well plate. Then  
158 the plate was automated by Biomek 4000 workstation (Beckman Coulter, Inc., Brea, USA) following  
159 preprogrammed protocol. Briefly, 100 µl ice cold methanol with partial internal standards was  
160 automatically added to each sample and vortexed vigorously for 5 min. The plate was centrifuged at 4000g  
161 for 30 min (Allegra X-15R, Beckman Coulter, Inc., Indianapolis, USA). Next, 30 µl of supernatant was  
162 transferred to a clean 96-well plate, and 20 µl of freshly prepared derivative reagents was added to each

163 well. The plate was sealed, and the derivatization was carried out at 30°C for 60 min. After derivatization,  
164 350 µl of ice-cold 50% methanol solution was added to dilute the sample. Then the plate was stored at -  
165 20°C for 20 min and followed by 4000g centrifugation at 4°C for 30 min. An ultra-performance liquid  
166 chromatography coupled to tandem mass spectrometry (UPLC-MS/MS) system (ACQUITY UPLC-Xevo  
167 TQ-S, Waters Corp., Milford, USA) was used to quantitate the metabolite in this project (**Figure 1B**).

168

### 169 *Sample processing*

170 The rapid turnover of many intracellular metabolites makes immediate metabolism quenching necessary.  
171 The extraction solvents were stored in -20°C freezer overnight and added to the samples immediately after  
172 the samples were thawed. An ice-salt bath was used to keep samples at a low temperature to minimize  
173 degradation during sample preparation. All the prepared samples were analyzed within 48 hours after  
174 extraction and derivatization. A comprehensive set of rigorous quality control/assurance (QC/QA)  
175 procedures was employed to ensure a consistently high quality of analytical results, throughout controlling  
176 every single step from sample receipt at laboratory to final deliverables. The goal of QC/QA was to  
177 provide the reliable data for biomarker discovery study. To achieve this, three types of quality control  
178 samples (test mixtures, internal standards, and pooled biological samples) were used in the metabolomics  
179 platform. In addition to the quality controls, conditioning samples, and solvent blank samples were also  
180 used for obtaining optimal instrument performance. Each sample was accessioned into Metabo-Profile  
181 LIMS system and was assigned by the LIMS a unique identifier, which was used to track all sample  
182 handling, tasks, results and other conditions. The samples and aliquots were barcoded and analyzed by the  
183 LIMS system.

184

### 185 *Metabonomic data analysis*

186 Data were analyzed using a XploreMET v3.0 system (Metabo-Profile, Shanghai, China). Partial least  
187 squares projection to latent structures and discriminant analysis (PLS-DA) were used to process the  
188 acquired GC-TOF/MS data. Principal component analysis (PCA) and partial least square discriminant  
189 analysis (PLS-DA) were performed for both positive and negative models after log transformation and  
190 pareto scaling. The variable importance in the projection value of each variable in the PLS-DA model was  
191 calculated to indicate its contribution to the classification. The significance of each metabolite with the  
192 VIP value >1 was assessed by Student's *t*-test at univariate level, and the results were adjusted for multiple  
193 testing using the Benjamini-Hochberg procedure with the critical false discovery rate (FDR) set to 0.05.

194

### 195 *Enrichment of plasma derived exosomes from peripheral blood*

196 Fresh whole blood samples from recruited patients or HCs were collected into the EDTA□2Na vacuum  
197 tubes and the blood was centrifuged at 1500 g for 15 min. The plasma was transferred into a new tube and  
198 centrifuged at 20,000 g at 4 °C for 15 min. The supernatant was collected and kept at -80 °C until use. The  
199 exosomes were isolated by size exclusion chromatography method as described previously with minor  
200 modifications (Boing *et al*, 2014). In brief, 2 ml of 0.8 µm-filtered plasma sample was purified using

201 Exosupur® columns (Echobiotech, China). The exosome samples were eluted with PBS and a total of 2  
202 mL eluate fractions were collected according to the manufacturer's instruction. Fractions were  
203 concentrated to 200 µl by 100 kDa molecular weight cut-off Amicon® Ultra spin filters (Merck, Germany).

204

#### 205 *Transmission electron microscopy and nanoparticle tracking analysis*

206 For transmission electron microscopy analysis (Varga *et al*, 2014), 10 µl of exosomal suspension was  
207 loaded on a continuous carbon grid, and incubated for 10 min at room temperature, followed by distilled  
208 water washing. After being absorbed excessively, each sample was negatively stained with 10 µl of 2%  
209 (w/v) uranyl acetate solution at room temperature for 1 min and sucked up residue by filter paper. Then,  
210 the samples were photographed at 80kv by a Hitachi H-7650 transmission electron microscope (Hitachi,  
211 Tokyo, Japan). Particle size and concentration of plasma-derived EVs were analyzed by nanoparticle  
212 tracking analysis (NTA) on a Nano Sight NS300 instrument (Malvern Panalytical, Malvern, UK)  
213 following the manufacturer's protocol (Varga *et al.*, 2014). In brief, the samples were diluted to  $1 \times 10^7 \sim$   
214  $1 \times 10^9$  particles/ml in PBS, and slowly injected into the sample pool and detected in flow mode. These flow  
215 measurements consisted of three measurements of 60 s. The captured data were analyzed using NTA 3.2  
216 software.

217

#### 218 *Library preparation and small RNA sequencing*

219 Total RNAs from exosomes were isolated using the miRNeasy® Mini kit (Qiagen, MD, USA) according  
220 to the manufacturer's protocol. Sequencing libraries were generated using the QIAseq miRNA Library Kit  
221 (Qiagen, MD, USA), according to the manufacturer's instructions. 500 ng of exosome derived total RNA  
222 for each sample was used as input for library preparation. The RNA samples were barcoded by ligation  
223 with unique adaptor sequences to allow pooling of samples. The elution containing pooled DNA library  
224 was further processed for cluster generation and sequencing using a NovaSeq 6000 platform.

225

#### 226 *Real-time PCR analysis*

227 To validate the miRNAs identified in RNA sequencing data, we performed qPCR analysis of selected  
228 miRNA targets. Total RNA extraction from the serum exosomes was performed with the miRNeasy®  
229 Mini kit (Qiagen, MD, USA) according to the manufacturer's instructions. The concentration and quality  
230 of the RNA was determined using the RNA Nano 6000 Assay Kit of the Agilent Bioanalyzer 2100 System  
231 (Agilent Technologies, CA, USA). Single strand cDNA was synthesized with the PrimeScript™ RT  
232 reagent Kit (Takara, Dalian, China). The RT-PCRs were conducted on an ABI Prism 7500 HT using the  
233 TaqMan Fast Advanced Master Mix. Real-time PCR amplification was performed in triplicate and a  
234 negative control was included for each primer. miRNA levels were normalized to average Ct of internal  
235 control has-miR-106a-5p in the confirmation phase.

236

#### 237 *Analysis of miRNA-predicted target genes and network visualization*

238 The miRNet (<http://www.mirnet.ca>) was used to predict mRNAs targets, conduct functional enrichment  
239 analysis and generate network visualization (Fan *et al*, 2016). The miRNA-target interaction data were  
240 based on 10 well-annotated databases including miRTarBase, TarBase, miRecords, SM2miR, Pharmaco-  
241 miR, miR2Disease, PhenomiR, StarBase, EpimiR, miRDB, in which the datasets were merged on the same  
242 targets for each species, removed the duplicate entries, updated the literature references and stored them  
243 into SQLite database for fast retrieval. The conventional hypergeometric tests were implemented in  
244 miRNet for functional annotations-based Disease, GO, or KEGG pathway analysis.

245

#### 246 *Stem cell culture and neurite outgrowth assay*

247 Human induced pluripotent stem cells (hiPSCs) were purchased from Guidon Pharmaceuticals (Beijing,  
248 China) and cultured in mTeSR™ Plus media (STEMCELL Technologies) for feeder-free maintenance and  
249 expansion. For neurite outgrowth assay,  $0.7 \times 10^5$  iPSCs/well were first seeded in a 24-well plate and  
250 neuronal differentiation from hiPSCs was conducted according to the protocol previous published (Zhang  
251 *et al*, 2013). Ectopic expression of targeted miRNA (pEZX-MR04 or pEZX-MR04-hsa-744-5p) via  
252 lentiviral transfection (250µl media + 50µl lentivirus + 4µg/ml polybrene) for 24 hours was applied on day  
253 4 of neuronal differentiation. Three, five and seven days after lentiviral induction of targeted miRNA  
254 expression and passage to a new dish, hiPSCs derived neurons were imaged at 20x magnification using  
255 CellInsight™ CX5 High Content Screening Platform (Thermo Scientific). Individual cell measurements of  
256 mean/median/maximum process length, total neurite outgrowth (sum of the length of all processes),  
257 number of processes, number of branches, cell body area, and mean outgrowth intensity were obtained  
258 using the HCS Studio™ 2.0 Cell Analysis Software (Thermo Scientific). Total RNA from cells was  
259 isolated using miRNeasy® Mini kit (Qiagen, MD, USA) according to the manufacturer's instructions.

260

#### 261 *DiR-labelled exosomes and in vivo biodistribution assay*

262 Female C57BL/6 mice (aged 6 to 8 weeks old) were kept under standard laboratory conditions. Mice were  
263 housed in a temperature-controlled room with a 12-hour light/dark cycle. The University of Kunming  
264 Medical University Committee on the Use and Care of Animals approved all experiments. The filtered  
265 exosome of serum sample from healthy donors was incubated with 1 mM fluorescent lipophilic tracer DiR  
266 (1,1-dioctadecyl-3,3,3,3-tetramethylindotricarbocyanine iodide) (D12731, Invitrogen, Life Technologies)  
267 at room temperature for 15 minutes prior to exosome isolation. Lipopolysaccharide (LPS) or PBS treated  
268 C57BL/6 mice ( $n = 3$ /group) were used and freshly purified DiR-labeled exosomes were injected through  
269 the tail vein for intravenous injections. The biodistribution of labeled exosomes was examined using  $2.0 \times$   
270  $10^{10}$  particles/gram body weight (p/g). The particle count was measured with NTA and the samples were  
271 diluted accordingly. For the analysis of DiR-exosome distribution, IVIS Spectrum (Perkin Elmer) was  
272 used. Either live (isoflurane sedated) mice were imaged, or the animals were sacrificed and then the organs  
273 harvested prior to analysis. For the perfusion experiment, the mice were sedated, and the vascular system  
274 was flushed by transcatheter perfusion for 5 minutes. The left ventricle was infused with PBS (5 ml/min)  
275 and the right atrium was perforated. After perfusion, the organs were harvested and analyzed.

276

### 277 *Statistical analysis and bioinformatics analysis*

278 All data were analyzed with R version 3.6.3. Kruskal–Wallis test or analysis of variance (ANOVA) test  
279 followed by a post-hoc test (Bonferroni's t test) was used to test for differences in continuous variables.  
280 Comparison between groups was performed using a Student's t test or a Chi-square analysis as appropriate.  
281 The Pearson correlation was used for correlation analyses. For miRNA sequencing, the raw fastq files  
282 generated from next-generation sequencing were preprocessed to remove adaptor sequences using the  
283 TagCleaner. Subsequently, known and novel miRNAs were detected within the preprocessed data using  
284 the miRDeep2 (Friedlander *et al*, 2012). Statistical analysis and significance were calculated using various  
285 tests and adjusted for multiple testing. Adjusted statistical significance was assessed as  $p < 0.05$ .

286

## 287 **Results**

### 288 *Characteristics of the study population*

289 A total of 120 patients with SUDs and 20 age-matched healthy participants (without SUDs) were recruited  
290 at the First Affiliated Hospital of Kunming Medical University. The characteristics of the study  
291 participants are presented in **Table 1**. There were no significant differences for any variables including age,  
292 BMI, substance dependence history, annual income, and education level between patients with SUDs and  
293 healthy participants in both discovery and validation cohorts (**Table 1**).

294 Substance use, depression, and anxiety frequently co-occur (Lai *et al*, 2015). To better understand  
295 whether the use of heroin or methamphetamine influences mood (specifically, anxiety and depression), the  
296 HAM-A and HAM-D questionnaires were administered by experienced interviewers. As expected, the  
297 HAM-A total scores were significantly increased in the HDPs ( $p = 0.0005$ ) and the MDPs ( $p = 0.0014$ )  
298 when compared to HCs in the discovery cohort (**Table 1**). Significant increases relative to HCs were  
299 observed in both HDPs and MDPs at the 3-month and 12-month stages after the initiation of withdrawal,  
300 respectively (**Table S1**). The overall differences in HAM-A for HDPs and MDPs relative to HCs, as well  
301 as the differences in the subgroups at the 3-month and 12-month withdrawal stages, were validated (**Table**  
302 **S2**). In contrast, the significant differences in HAM-D scores observed in the HDPs ( $p = 0.0134$ ) in the  
303 discovery cohort did not persist in the validation cohort. In the subsequent subgroup analysis, the  
304 significant increases in HAM-D scores were only validated in the subgroup of MDPs at the 3-month  
305 withdrawal stage, but not in any of the subgroups for HDPs (**Tables S1 & S2**).

306

307 *Dynamic changes in peripheral neurotransmitters during substance withdrawal* In order to reveal  
308 peripheral neurotransmitter changes in the patients with SUDs, we analyzed the classic neurotransmitters  
309 and their metabolites, including  $\gamma$ -aminobutyric acid (GABA), glutamate, serotonin, tryptophan,  
310 kynurenine, choline, etc, through UPLC-MS/MS (**Table S3 and Figure 1B**). Plasma samples from the 70  
311 participants in the discovery cohort were analyzed first for the 14 neurotransmitter metabolites. Of these,  
312 seven fell below the lower level of quantitation in  $> 20\%$  of samples and were excluded from analysis.  
313 Detailed results for the seven neurotransmitters are presented in **Table 2**. Our analysis revealed that three

314 of the seven neurotransmitters were associated with significant changes. Two neurotransmitters, GABA  
315 and choline, were significantly decreased in both HDPs ( $fdr.p.GABA = 0.0026$ ,  $fdr.p.choline = 0.026$ ) and  
316 MDPs ( $fdr.p.GABA = 0.0009$ ,  $fdr.p.choline = 0.026$ ) relative to HCs, respectively. In contrast, serotonin  
317 was significantly increased in HDPs ( $fdr.p.serotonin = 0.0001$ ) and MDPs ( $fdr.p.serotonin = 0.0013$ )  
318 relative to HCs (**Table 2 and Figure S1**). These significant differences in plasma GABA, choline, and  
319 serotonin were further validated in the independent cohort (**Table S4**). Interestingly, there were no  
320 significant differences in the tested neurotransmitters between HDPs and MDPs (**Table 2 & S4**).

321 Next, to investigate potentially differential neurotransmitters in SUDs across the various  
322 withdrawal stages, we performed additional subgroup analyses. Notably, significant increases in serotonin  
323 were observed in all three subgroups of HDPs and two subgroups of MDPs when compared to HCs, but  
324 not observed in the subgroup of MDPs at the 12-month withdrawal stage (**Table 3**). In contrast, the  
325 significant decrease in GABA persisted in all three subgroups of MDPs relative to HCs but was only found  
326 in the HDPs at the 3-month withdrawal stage. Moreover, the significant decreases in choline were only  
327 observed in the subgroups of HDPs and MDPs at the 3-month withdrawal stage (**Table 3**). To validate  
328 these findings, the plasma neurotransmitter profiles across the three withdrawal stages were further tested  
329 in an independent cohort. Compared to HCs, the significant differences in serotonin at the 7-day  
330 withdrawal stage, as well as in GABA, choline, and serotonin at the 3-month withdrawal stage were  
331 validated in both HDPs and MDPs, respectively (**Table S5**).

332

### 333 *Associations of neurotransmitters and psychiatric comorbidities in SUD patients*

334 To further determine the associations between neurotransmitters and psychiatric comorbidities in SUDs,  
335 Pearson correlations between neurotransmitters (GABA, choline, and serotonin) and HAM-A/D scales  
336 were conducted. The plasma GABA in HDPs ( $R = -0.40$ ,  $p = 0.01$ ) and MDPs ( $R = -0.35$ ,  $p = 0.03$ ) was  
337 significantly correlated with HAM-A scores. However, the significant correlation between GABA and  
338 HAM-D scores was only observed in MDPs ( $R = -0.43$ ,  $p = 0.0052$ ) but not HDPs ( $R = -0.20$ ,  $p = 0.21$ ). In  
339 addition, significant correlations were found between plasma serotonin and HAM-A score in both HDPs  
340 ( $R = 0.44$ ,  $p = 0.0054$ ) and MDPs ( $R = 0.40$ ,  $p = 0.0012$ ). Nevertheless, no significant correlation was  
341 observed between serotonin and the HAM-D score, or between choline and the HAM-A/D scores (**Figure**  
342 **S2**). In summary, these results indicate some strong correlations between specific plasma neurotransmitters  
343 and withdrawal symptoms and suggest that the dynamic changes in peripheral GABA and serotonin may  
344 play a key role in influencing moods during withdrawal.

345

### 346 *Isolation and characterization of plasma exosomes*

347 Despite research efforts in the field since the discovery of exosomes in peripheral circulation (Raposo &  
348 Stoorvogel, 2013), the role of exosomes in the pathophysiology of psychiatric disorders, and especially  
349 SUDs, remains poorly understood. In the present study, plasma exosomes were isolated from patients with  
350 SUDs and age-matched HCs by size exclusion chromatography in the discovery cohort, and their  
351 morphology was verified by transmission electron microscopy (TEM) and nanoparticle tracking analysis

352 (NTA), as shown in **Figure 1D & E**. These analyses revealed an average particle diameter of 40–140 nm,  
353 and there was no significant difference in the exosome size distribution between the patients with SUDs  
354 and HCs (data not shown). In addition, the exosomes were verified by detecting the expression of  
355 exosomal surface markers CD81 and CD63 (Ricklefs *et al*, 2019) using western blotting (**Figure 1F**),  
356 which confirmed the successful exaction of exosomes from plasma samples.

357

### 358 *Differential expression of exosomal miRNA between SUD patients and healthy controls*

359 To gain insight into the transcriptional dynamics of exosomes, small RNA sequencing was applied to the  
360 total RNA derived from plasma exosomes in all 70 participants in the discovery cohort. Sequencing quality  
361 statistics are shown in **Table S6**. Top RNA species detected by sequencing included miRNA, piRNA,  
362 tRNA, and snoRNA, and the percentage of reads assigned to each species and the number of mapped  
363 miRNAs did not significantly differ between samples (**Figure S3**). Length distribution analysis of the  
364 miRNAs showed that 20–24 nucleotides (nt) was the most frequent read length, with the peak at 22 nt  
365 (**Table S7**), indicating that mature miRNAs were suitably enriched during the sequencing library  
366 preparation process. To focus on the miRNA ubiquitously abundant in plasma and suitable as biomarker  
367 candidates, we selected the miRNA candidates with an absolute fold change in expression of  $\geq 1.5$ , a  
368 nominal FDR value of  $\leq 0.05$ , and the expression (RPKM  $\geq 0$ ) across  $\geq 50\%$  of samples. This yielded 43  
369 and 26 miRNAs with significant changes in HDPs and MDPs relative to HCs, respectively (**Figure 2A-D**,  
370 **Table S8 & S9**). The Venn diagram displays a list of 20 shared differentially expressed miRNAs (DE-  
371 miRNAs) in HDPs and MDPs when compared to HCs (**Figure 2E, Table 4**), suggesting there might be a  
372 variety of shared, exosomal miRNA-associated, substance-related functional abnormalities between HDPs  
373 and MDPs.

374

### 375 *Pathway analysis and gene target and gene ontology prediction*

376 Network visualization and functional enrichment analysis is a powerful combination in delivering  
377 important biological insights. Using miRNet, a network-based visual exploration and functional  
378 interpretation platform (Chang *et al*, 2020), we identified predicted functional pathways associated with  
379 mRNA targets of the 20 shared DE-miRNAs and thereafter generated an miRNA-mRNA interacting  
380 network (**Figure 2E-G**). Top associated pathway/disease hits included mental and motor retardation ( $p =$   
381  $5.2e-24$ ), cognitive delay ( $p = 4.2e-23$ ), global developmental delay ( $p = 3.8e-22$ ), with a strong overall  
382 theme of developmental or intellectual abnormality (**Figure 2F-G**). Next, the differential metabolites and  
383 miRNAs were combined and used to perform ROC analysis to identify an optimal metabolite and/or  
384 exosomal miRNA biomarker panel in plasma for SUDs. Strikingly, from the ROC curves, the calculated  
385 sensitivities and specificities of the miRNA in diagnosing SUDs and distinguishing HDPs and MDPs were  
386 identified (**Figure 2H-K**). Notably, the analysis of hsa-miR-451a and hsa-miR-21a resulted in an AUC of  
387 0.966 and 0.861, suggesting that these plasma exosomal miRNA, especially has-miR-451a and has-miR-  
388 21-5p, could serve as additional indicators for monitoring substance dependence and withdrawal. In order  
389 to verify the accuracy of miRNA-seq, hsa-miR-451a and hsa-miR-21-5p were selected as mentioned above

390 for RT-qPCR analysis. The results indicated that the expression patterns of hsa-miR-451a and hsa-miR-21-  
391 5p were similar between small RNA-Seq and RT-qPCR (**Figure S4**).

392

### 393 *Identification of exosomal miRNA signatures across heroin and methamphetamine withdrawal*

394 We further investigated the changes in exosomal miRNAs in SUDs across the three withdrawal stages.  
395 When small RNA-seq data were subjected to weighted gene co-expression network analysis (WGCNA)  
396 (Langfelder & Horvath, 2008), multiple gene-network modules were obtained. We decided to focus mainly  
397 on the modules that could represent the dynamic changes of miRNA expression throughout withdrawal  
398 stages. Analysis of the module-trait relationship identified six unique modules (blue, brown, magenta,  
399 purple, pink, and cyan) correlated with the type of substance use or the stage of withdrawal ( $p < 0.05$ ). The  
400 six modules represent different miRNA expression alteration patterns (**Figure 3A-B**). Hub gene/miRNA  
401 network analysis of the modules revealed that a hierarchical organization of highly connected  
402 gene/miRNA in each module, through key controlling genes/miRNAs in the modular network could be  
403 identified. Notably, the blue module miRNAs (e.g., hsa-miR-140-3p) were mainly elevated at the 3-month  
404 withdrawal stage for both HDPs and MDPs (**Figure 3C-D**). The purple module consisting of miRNAs  
405 significantly decreased at all three withdrawal stages (e.g., hsa-miR-92a-3p and hsa-miR-451a, **Figure 3E-**  
406 **F**). Different from the miRNAs in the blue module which showed an increase at the 3-month withdrawal  
407 stage, the miRNAs in the brown module were significantly increased at both the 7-day and 3-month stages  
408 (e.g., hsa-miR-139-3p, **Figure 3G-H**). By contrast, the miRNAs in the pink module were significantly  
409 decreased at both the 3-month and 12-month stages (e.g., hsa-miR-375-3p, **Figure 3I-J**). Moreover, the  
410 miRNAs in modules magenta and cyan had other interesting but unique expression patterns across  
411 withdrawal stages (**Figure 3K-N**).

412 We then sought to investigate the relationships between the neurotransmitters (GABA, choline,  
413 and serotonin) and the hub gene/miRNA in the blue and brown modules using Spearman's correlations.  
414 One exciting finding was that hsa-miR-140-3p from the blue module showed strong negative correlations  
415 ( $p < 0.01$ ) with both GABA and choline (**Figure S5A-B**). The hsa-miR-744-5p in the brown module was  
416 positively correlated with serotonin in HDPs ( $p = 4.9e-5$ ) and MDPs ( $p = 0.032$ ) (**Figure S5C**). Taken  
417 together, the WGCNA and the correlation analyses revealed a dynamic expression pattern of miRNA  
418 signatures during both heroin and methamphetamine withdrawal, and a range of neurotransmitter  
419 associated exosomal miRNAs in the peripheral blood plasma of patients with SUDs.

420

### 421 *Effects of hsa-miR-744-5p on neurite outgrowth in human iPSC derived neurons*

422 Emerging studies have indicated an important role for specific miRNA in neural differentiation,  
423 proliferation, and maturation during embryonic development and/or disease progression using neurite  
424 outgrowth assays (Agostini *et al*, 2011; Le *et al*, 2009). To ascertain the neuronal function and molecular  
425 mechanism of hsa-miR-744-5p, we differentiated hiPSCs to neurons and infected them with lentivirus-  
426 miR-744-5p or scrambled control (**Figure 4A-B**). As illustrated in **Figure 4C**, across three replicate  
427 experiments, when iPSC derived neurons were treated with a scrambled control, there was no decrease in

428 relative total outgrowth and cell viability. By contrast, overexpression of hsa-miR-744-5p was sufficient to  
429 cause significant decreases in neurite processes (**Figure 4D-F**). For further characterization, genome-wide  
430 gene expression changes upon miRNA transfection were studied using RNA-seq and comparative  
431 transcriptome analysis on hiPSCs derived neuronal culture with ectopic hsa-miR-744-5p expression versus  
432 scrambled control. One day after the lentivirus infection, a list of 46 genes were differentially expressed  
433 with a cut-off (fold change  $\leq -1.5$  or  $\geq 1.5$ ,  $p \leq 0.05$ ), in which the differentially expressed genes (DEGs)  
434 were mainly over-represented in axon development ( $p = 2.0e-3$ ), reproductive process ( $p = 5.5e-3$ ) and  
435 system development ( $p = 7.6e-3$ ) (**Figure 4G-H**). Likewise, 556 DEGs with the same cut-off were  
436 identified on day 3 after the induction of hsa-miR-744-5p expression in hiPSCs derived neuronal culture  
437 and these DEGs were mainly enriched for cell cycle arrest ( $p = 1.1e-3$ ), cell growth ( $p = 1.8e-3$ ), and  
438 positive regulation of neuron apoptotic process ( $p = 2.4e-3$ ) (**Figure 4I-J**). RNA-seq data may partly  
439 demonstrate secondary effects on global mRNA expression, while gene expression changes are triggered  
440 by primary miRNA targets. Therefore, to discriminate between primary and secondary target genes, the  
441 differential expression results obtained from the RNA-seq analysis were compared to potential hsa-miR-  
442 744-5p targets predicted by bioinformatic algorithms. The overlap of statistically significant DEGs and  
443 bioinformatically predicted target genes revealed that hsa-miR-744-5p may play a significant role  
444 involving neural development and function regulating its primary miRNA targets PSENEN, FDX1L,  
445 VPS37D, SPTBN4, PPP5C, and FAM57B (**Figure 4K**), although their mechanisms require further  
446 investigation. Overall, the neurite outgrowth assays and RNA-seq analyses reveal an important role of hsa-  
447 miR-744-5p in maintaining neuronal development and function.

448

## 449 Discussion

450 Herein, we report the dynamics of neurotransmitter and exosomal miRNA profiles in the peripheral  
451 circulation of 120 patients with SUDs and 20 healthy participants using UPLC-MS/MS and high-  
452 throughput sequencing technologies. After controlling for various factors (age, BMI, substance  
453 dependence history, annual income, and education), we successfully identified a set of critical miRNAs in  
454 circulating exosomes that were associated with neurotransmitters and the psychological comorbidities in  
455 these patients undergoing withdrawal. *In vitro* studies showed that increased hsa-miR-744-5p, one of key  
456 exosomal miRNAs, inhibited neurite outgrowth human iPSC derived neurons and may play a significant  
457 role in neural function by crossing BBB and regulating its primary gene targets.

458 Detoxification represents an important initial phase in the long-term recovery process by relieving  
459 withdrawal discomfort (Bart, 2012). To date, although a cascade of neurotransmitter and neuroendocrine  
460 abnormalities and neuronal damage are well-recognized consequences following long-term abuse of illegal  
461 substances, only limited molecular biomarkers have been identified for the associated symptoms (Volkow  
462 *et al*, 2015). Diagnosis is thus mainly left to the use of subjective questionnaires, particularly during the  
463 detoxification stage within the first 3 to 6 months (Stein *et al*, 2020; Timko *et al*, 2019). We observed that  
464 the plasma serotonin was significantly increased in patients with SUDs and anxiety (HAM-A) was  
465 significantly correlated with higher plasma serotonin concentration as compared with HCs, supporting the

466 notion that changes in plasma serotonin seem to be more associated with the presence of psychiatric  
467 comorbidity than other neurotransmitters such as GABA and choline (Araos *et al*, 2019; Fava *et al*, 2018).  
468 While changes in the kynurenine pathway appear to be directly associated with a history of alcohol use  
469 disorder (AUD), altered tryptophan concentrations are associated with the presence of comorbid  
470 psychiatric disorders (Vidal *et al*, 2020). However, we did not observe a significant change in plasma  
471 kynurenine or tryptophan in individuals with SUDs, suggesting that AUD and SUDs might have different  
472 underlying mechanisms.

473 In the literature, emerging evidence has been documented for the importance of exosomes in the  
474 diagnosis, prognosis, and therapy of neurological and psychological disorders (van Niel *et al*, 2018).  
475 Exosomes carry abundant mRNA, DNA, miRNA, lncRNA, and other nucleic acid species, which provides  
476 strong support for the use of exosomes as biomarkers obtained via liquid biopsy (O'Brien *et al*, 2020).  
477 Specifically, the contents of exosomes are stable and can be delivered into recipient cells to exert their  
478 biological functions, indicating that the exosome-derived DNA/RNA could be used to account for the  
479 molecular regulation of diseases and reflect the conditional state/progression. Using small RNA  
480 sequencing, the present study uncovered insights into the dynamic expression pattern of miRNAs in the  
481 exosomes at various stages of substance withdrawal. First, we have identified a set of dysregulated miRNA  
482 signatures including hsa-miR-451a and hsa-miR-21a, with an AUC of 0.966 and 0.861, respectively, for  
483 predicting and distinguishing patients with HDPs and MDPs. Second, specific trends of change (i.e.,  
484 increases, decreases, and combinations of both) of miRNA content in exosomes as a function of  
485 withdrawal stage were also identified. Although the underlying mechanism require further investigation,  
486 the possible functions of several dysregulated exosomal miRNAs have been proposed in other studies. For  
487 example, ethanol exposure increases hsa-miR-140-3p in extracellular vesicles, which may result in  
488 aberrant neural progenitor cell growth and maturation, explaining brain growth deficits associated with  
489 prenatal alcohol exposure (Keller *et al*, 2017; Tseng *et al*, 2019). We showed that the exosomal hsa-miR-  
490 140-3p is mainly elevated at the 3-month withdrawal stage in plasma for both HDPs and MDPs, and it was  
491 negatively correlated plasma GABA and choline, indicating that the plasma exosomal hsa-miR-140-3p  
492 could be recognized as a stage specific biomarker. The data also supports the computational prediction that  
493 hsa-miR-140-3p is involved in GABA and/or choline associated regulatory network (Ntoumou *et al*, 2017;  
494 Zhao *et al*, 2012). Overall, the analysis of exosomal miRNA could become a promising diagnostic strategy  
495 to monitor withdrawal symptoms in the context of SUDs.

496 Furthermore, an increase of exosomal hsa-miR-744-5p has been identified in patients with SUDs  
497 at the short-term withdrawal stage and it is positively correlated with serotonin concentration in the serum  
498 in both HDPs and MDPs (**Figure S5**). Previous studies have also shown that hsa-miR-744-5p inhibits cell  
499 proliferation and invasion in pituitary oncocytoma and epithelial ovarian cancer (Chen *et al*, 2019a;  
500 Krokker *et al*, 2019; Zhao *et al*, 2020). Herein, we performed bioinformatical analysis and identified genes  
501 PSENEN, FDX1L, VPS37D, SPTBN4, PPP5C, and FAM57B, as potential targets of hsa-miR-744-5p  
502 (**Figure 4K**). PSENEN, as a key regulator of the gamma-secretase complex which is involved in the  
503 production of the amyloid beta 42 peptides, has been reported to be associated with late onset Alzheimer's

504 disease (Jia *et al.*, 2007; Nam *et al.*, 2011). In addition, SPTBN4 disorder is characterized by severe-to-  
505 profound developmental delay and/or intellectual disability (Wang *et al.*, 2018), while DNA methylation-  
506 associated silencing in SPTBN4 was also identified in patients with Alzheimer's disease (Sanchez-Mut *et*  
507 *al.*, 2013). Therefore, we speculate that hsa-744-5p may regulate key neuronal genes PSENEN and  
508 SPTBN4 to suppress neurogenesis and contribute to the neurological and/or psychological symptoms  
509 observed in patients with SUDs.

510 More importantly, these above findings point towards unknown mechanisms in patients with  
511 SUDs that dysregulated exosomal miRNAs may be functioning directly on CNS. Several studies have  
512 shown the capability of exosomes to cross the BBB and communicate between the peripheral circulation  
513 and the CNS (Chen *et al.*, 2016; Saeedi *et al.*, 2019). In the present study, we labeled exosomes from  
514 human serum with DiR, injected them via the tail vein of C57/BL6 mice, and imaged them 24 hours after  
515 injection using an *in vivo* imaging system. Of note, DiR-labeled exosomes were successfully captured in  
516 the brain and other organs (Figure S6A-C). We further compared the ability of exosomes crossing the  
517 BBB in the mice with or without LPS treatment. Interestingly, a significant increase in DiR-labeled  
518 exosomes was captured and measured in the brain from LPS treated mice (Figure S6D), suggesting that  
519 we are indeed tracking labeled exosomes crossing the BBB and more exosomes crossing the BBB when  
520 permeability is disrupted by LPS treatment and inflammation (Banks *et al.*, 2015; Banks *et al.*, 2020).  
521 However, the biogenesis of exosomes across endothelial cells is a relatively unexplored area and it is  
522 unknown whether the changes in miRNAs between the CNS and the peripheral circulation could be due to  
523 off-loading miRNA cargo for endothelial regulation or other possible factors. Future studies may unravel  
524 how exosomes change through membrane barriers of the brain and various organs in the periphery before  
525 circulating in the bloodstream.

526 The fact, although both heroin and methamphetamine are highly addictive and dangerous drugs,  
527 they belong to two different categories of addictive substances, opiates and stimulants, respectively,  
528 leading to distinct major effects and their acting through different mechanisms. Surprisingly, we observed  
529 a large overlap in heroin and methamphetamine induced neurotransmitter and exosomal miRNA changes  
530 during withdrawal. Thus, future longitudinal studies with larger sample sizes will be needed to uncover the  
531 subtle differences between heroin and methamphetamine induced changes. The presented study also  
532 entails limitations due to the protocol and the patient chosen. Due to the protocol applied, we only profiled  
533 the exosomal miRNAs and the neurotransmitters present in plasma. However, the origin of these exosomes  
534 with dysregulated miRNAs has not been identified. Further biological studies and more laborious  
535 techniques such as proteomics should address the origin of these exosomes with dysregulated miRNAs.

536 In conclusion, to the best of our knowledge, this study has the largest sample size in the field to  
537 date and performed in a controlled setting to correlate the severity of substance withdrawal stress with  
538 alterations in plasma neurotransmitter and exosomal miRNA expression profiles. By using UPLC-MS/MS  
539 and high-throughput sequencing approaches and by including an extensive functional validation analysis,  
540 we have identified a set of neurotransmitters associated exosomal miRNAs which may elucidate the  
541 molecular mechanism of how the peripheral circulation communicates with the CNS and contributes to the

542 symptoms associated with substance dependence and withdrawal. We also demonstrated plausible  
543 mechanistic links in an *in vitro* neuronal model and the signaling pathways in which they operate. Overall,  
544 these data add to a growing literature that implicates plasma exosomal miRNAs as functional mediators of  
545 neuronal function and development processes of withdrawal symptoms.

546

#### 547 **Author contributions**

548 JH.Y. and KH.W. designed the study and supervised the project. Y.X., FR.C., ZY.Z., ZR.X., YR.M., L.Z.,  
549 YQ.K., J.L., Y.W. and M.Z. collected the data. JH.Y., K.S., HJ.W. and QY.P. did the data analysis and  
550 interpretation. JH.Y. took the lead in writing the manuscript. T.T. and T.W.R. discussed the results and  
551 contributed to the final manuscript. All authors reviewed the report and approved the final version.

552

#### 553 **Acknowledgments**

554 Foremost, we would like to thank Yongjin Zhang and Limei Cao for their expert technique assistance. This  
555 work was supported by grants from the National Natural Science Foundation of China (Grant No.  
556 3171101074, 81860100, 31860306, and 81870458), Science and Technology Department of Yunnan  
557 Province (Grant No. 2018DH006, 2018NS0086, 202001AV070010), Yunnan Province Clinical Research  
558 Center (2019ZF012), and Yunling Scholar (Grant No. YLXL20170002).

559

#### 560 **Data and material availability**

561 The clinical data of the patients used to support the findings of this study are included within the  
562 article. The original sequencing data of the microRNA used to support the findings of this study are  
563 available at PRJNA667326 of NCBI Sequence Read Archive (SRA).

564

#### 565 **Reference**

566 Agostini M, Tucci P, Steinert JR, Shalom-Feuerstein R, Rouleau M, Aberdam D, Forsythe ID,  
567 Young KW, Ventura A, Concepcion CP *et al* (2011) microRNA-34a regulates neurite  
568 outgrowth, spinal morphology, and function. *Proc Natl Acad Sci U S A* 108: 21099-21104  
569 Araos P, Vidal R, O'Shea E, Pedraz M, Garcia-Marchena N, Serrano A, Suarez J, Castilla-  
570 Ortega E, Ruiz JJ, Campos-Cloute R *et al* (2019) Serotonin is the main tryptophan metabolite  
571 associated with psychiatric comorbidity in abstinent cocaine-addicted patients. *Sci Rep* 9:  
572 16842  
573 Banks WA, Gray AM, Erickson MA, Salameh TS, Damodarasamy M, Sheibani N, Meabon  
574 JS, Wing EE, Morofuji Y, Cook DG *et al* (2015) Lipopolysaccharide-induced blood-brain  
575 barrier disruption: roles of cyclooxygenase, oxidative stress, neuroinflammation, and  
576 elements of the neurovascular unit. *J Neuroinflammation* 12: 223  
577 Banks WA, Sharma P, Bullock KM, Hansen KM, Ludwig N, Whiteside TL (2020) Transport  
578 of Extracellular Vesicles across the Blood-Brain Barrier: Brain Pharmacokinetics and Effects  
579 of Inflammation. *Int J Mol Sci* 21  
580 Bart G (2012) Maintenance medication for opiate addiction: the foundation of recovery. *J*  
581 *Addict Dis* 31: 207-225  
582 Bayer R, Franke H, Ficker C, Richter M, Lessig R, Buttner A, Weber M (2015) Alterations  
583 of neuronal precursor cells in stages of human adult neurogenesis in heroin addicts. *Drug*  
584 *Alcohol Depend* 156: 139-149

- 585 Bell J, Strang J (2020) Medication Treatment of Opioid Use Disorder. *Biol Psychiatry* 87:  
586 82-88
- 587 Boing AN, van der Pol E, Grootemaat AE, Coumans FA, Sturk A, Nieuwland R (2014)  
588 Single-step isolation of extracellular vesicles by size-exclusion chromatography. *J Extracell*  
589 *Vesicles* 3
- 590 Brady KT (2019) Improving Our Understanding of Substance Use Disorders. *Am J*  
591 *Psychiatry* 176: 87-89
- 592 Buttner A, Weis S (2006) Neuropathological alterations in drug abusers : The involvement of  
593 neurons, glial, and vascular systems. *Forensic Sci Med Pathol* 2: 115-126
- 594 Carrico AW, Johnson MO, Morin SF, Remien RH, Riley ED, Hecht FM, Fuchs D (2008)  
595 Stimulant use is associated with immune activation and depleted tryptophan among HIV-  
596 positive persons on anti-retroviral therapy. *Brain Behav Immun* 22: 1257-1262
- 597 Chang L, Zhou G, Soufan O, Xia J (2020) miRNet 2.0: network-based visual analytics for  
598 miRNA functional analysis and systems biology. *Nucleic Acids Res* 48: W244-W251
- 599 Chen CC, Liu L, Ma F, Wong CW, Guo XE, Chacko JV, Farhoodi HP, Zhang SX, Zimak J,  
600 Segaliny A *et al* (2016) Elucidation of Exosome Migration across the Blood-Brain Barrier  
601 Model In Vitro. *Cell Mol Bioeng* 9: 509-529
- 602 Chen F, Zou L, Dai Y, Sun J, Chen C, Zhang Y, Peng Q, Zhang Z, Xie Z, Wu H *et al* (2021)  
603 Prognostic plasma exosomal microRNA biomarkers in patients with substance use disorders  
604 presenting comorbid with anxiety and depression. *Sci Rep* 11: 6271
- 605 Chen S, Shi F, Zhang W, Zhou Y, Huang J (2019a) miR-744-5p Inhibits Non-Small Cell  
606 Lung Cancer Proliferation and Invasion by Directly Targeting PAX2. *Technol Cancer Res*  
607 *Treat* 18: 1533033819876913
- 608 Chen T, Wang C, Yu H, Ding M, Zhang C, Lu X, Zhang CY, Zhang C (2019b) Increased  
609 urinary exosomal microRNAs in children with idiopathic nephrotic syndrome. *EBioMedicine*  
610 39: 552-561
- 611 Cheng L, Doecke JD, Sharples RA, Villemagne VL, Fowler CJ, Rembach A, Martins RN,  
612 Rowe CC, Macaulay SL, Masters CL *et al* (2015) Prognostic serum miRNA biomarkers  
613 associated with Alzheimer's disease shows concordance with neuropsychological and  
614 neuroimaging assessment. *Mol Psychiatry* 20: 1188-1196
- 615 Cruickshank CC, Dyer KR (2009) A review of the clinical pharmacology of  
616 methamphetamine. *Addiction* 104: 1085-1099
- 617 Downey LA, Loftis JM (2014) Altered energy production, lowered antioxidant potential, and  
618 inflammatory processes mediate CNS damage associated with abuse of the psychostimulants  
619 MDMA and methamphetamine. *Eur J Pharmacol* 727: 125-129
- 620 Duman RS, Sanacora G, Krystal JH (2019) Altered Connectivity in Depression: GABA and  
621 Glutamate Neurotransmitter Deficits and Reversal by Novel Treatments. *Neuron* 102: 75-90
- 622 Fan Y, Siklenka K, Arora SK, Ribeiro P, Kimmins S, Xia J (2016) miRNet - dissecting  
623 miRNA-target interactions and functional associations through network-based visual analysis.  
624 *Nucleic Acids Res* 44: W135-141
- 625 Fava GA, Benasi G, Lucente M, Offidani E, Cosci F, Guidi J (2018) Withdrawal Symptoms  
626 after Serotonin-Noradrenaline Reuptake Inhibitor Discontinuation: Systematic Review.  
627 *Psychother Psychosom* 87: 195-203
- 628 Friedlander MR, Mackowiak SD, Li N, Chen W, Rajewsky N (2012) miRDeep2 accurately  
629 identifies known and hundreds of novel microRNA genes in seven animal clades. *Nucleic*  
630 *Acids Res* 40: 37-52
- 631 Hamilton M (1959) The assessment of anxiety states by rating. *Br J Med Psychol* 32: 50-55
- 632 Hamilton M (1960) A rating scale for depression. *J Neurol Neurosurg Psychiatry* 23: 56-62

- 633 Huang C, Fisher KP, Hammer SS, Navitskaya S, Blanchard GJ, Busik JV (2018) Plasma  
634 Exosomes Contribute to Microvascular Damage in Diabetic Retinopathy by Activating the  
635 Classical Complement Pathway. *Diabetes* 67: 1639-1649
- 636 Jia L, Ye J, L VH, Wang W, Zhou C, Zhang X, Xu J, Wang L, Jia J (2007) Genetic  
637 association between polymorphisms of Pen2 gene and late onset Alzheimer's disease in the  
638 North Chinese population. *Brain Res* 1141: 10-14
- 639 Keller RF, Kanlikilicer P, Dragomir A, Fan Y, Akay YM, Akay M (2017) Investigating the  
640 Effect of Perinatal Nicotine Exposure on Dopaminergic Neurons in the VTA Using miRNA  
641 Expression Profiles. *IEEE Trans Nanobioscience* 16: 843-849
- 642 Kourrich S, Calu DJ, Bonci A (2015) Intrinsic plasticity: an emerging player in addiction.  
643 *Nat Rev Neurosci* 16: 173-184
- 644 Krokker L, Nyiro G, Reiniger L, Darvasi O, Szucs N, Czirjak S, Toth M, Igaz P, Patocs A,  
645 Butz H (2019) Differentially Expressed miRNAs Influence Metabolic Processes in Pituitary  
646 Oncocytoma. *Neurochem Res* 44: 2360-2371
- 647 Lai HM, Cleary M, Sitharthan T, Hunt GE (2015) Prevalence of comorbid substance use,  
648 anxiety and mood disorders in epidemiological surveys, 1990-2014: A systematic review and  
649 meta-analysis. *Drug Alcohol Depend* 154: 1-13
- 650 Langfelder P, Horvath S (2008) WGCNA: an R package for weighted correlation network  
651 analysis. *BMC Bioinformatics* 9: 559
- 652 Le MT, Xie H, Zhou B, Chia PH, Rizk P, Um M, Udolph G, Yang H, Lim B, Lodish HF  
653 (2009) MicroRNA-125b promotes neuronal differentiation in human cells by repressing  
654 multiple targets. *Mol Cell Biol* 29: 5290-5305
- 655 Lehmann SW, Fingerhood M (2018) Substance-Use Disorders in Later Life. *N Engl J Med*  
656 379: 2351-2360
- 657 Macedo TR, Ribeiro CA, Morgadinho T, Abreu MA (1998) Influence of concurrent heroin  
658 and cocaine abuse on the adrenergic and serotonergic systems in man. *Ann N Y Acad Sci* 844:  
659 208-213
- 660 Muller CP, Homberg JR (2015) The role of serotonin in drug use and addiction. *Behav Brain*  
661 *Res* 277: 146-192
- 662 Nam SH, Seo SJ, Goo JS, Kim JE, Choi SI, Lee HR, Hwang IS, Jee SW, Lee SH, Bae CJ *et*  
663 *al* (2011) Pen-2 overexpression induces Abeta-42 production, memory defect, motor activity  
664 enhancement and feeding behavior dysfunction in NSE/Pen-2 transgenic mice. *Int J Mol Med*  
665 28: 961-971
- 666 Norman LR, Basso M, Kumar A, Malow R (2009) Neuropsychological consequences of HIV  
667 and substance abuse: a literature review and implications for treatment and future research.  
668 *Curr Drug Abuse Rev* 2: 143-156
- 669 Ntounou E, Tzetis M, Braoudaki M, Lambrou G, Poulou M, Malizos K, Stefanou N,  
670 Anastasopoulou L, Tsezou A (2017) Serum microRNA array analysis identifies miR-140-3p,  
671 miR-33b-3p and miR-671-3p as potential osteoarthritis biomarkers involved in metabolic  
672 processes. *Clin Epigenetics* 9: 127
- 673 O'Brien K, Breyne K, Ughetto S, Laurent LC, Breakefield XO (2020) RNA delivery by  
674 extracellular vesicles in mammalian cells and its applications. *Nat Rev Mol Cell Biol* 21: 585-  
675 606
- 676 Oehmichen M, Meissner C, Reiter A, Birkholz M (1996) Neuropathology in non-human  
677 immunodeficiency virus-infected drug addicts: hypoxic brain damage after chronic  
678 intravenous drug abuse. *Acta Neuropathol* 91: 642-646
- 679 Pignatelli M, Bonci A (2015) Role of Dopamine Neurons in Reward and Aversion: A  
680 Synaptic Plasticity Perspective. *Neuron* 86: 1145-1157
- 681 Ramirez SH, Andrews AM, Paul D, Pachter JS (2018) Extracellular vesicles: mediators and  
682 biomarkers of pathology along CNS barriers. *Fluids Barriers CNS* 15: 19

- 683 Raposo G, Stoorvogel W (2013) Extracellular vesicles: exosomes, microvesicles, and friends.  
684 *J Cell Biol* 200: 373-383
- 685 Ricklefs FL, Maire CL, Reimer R, Duhrsen L, Kolbe K, Holz M, Schneider E, Rissiek A,  
686 Babayan A, Hille C *et al* (2019) Imaging flow cytometry facilitates multiparametric  
687 characterization of extracellular vesicles in malignant brain tumours. *J Extracell Vesicles* 8:  
688 1588555
- 689 Saeedi S, Israel S, Nagy C, Turecki G (2019) The emerging role of exosomes in mental  
690 disorders. *Transl Psychiatry* 9: 122
- 691 Sanchez-Mut JV, Aso E, Panayotis N, Lott I, Dierssen M, Rabano A, Urdinguio RG,  
692 Fernandez AF, Astudillo A, Martin-Subero JI *et al* (2013) DNA methylation map of mouse  
693 and human brain identifies target genes in Alzheimer's disease. *Brain* 136: 3018-3027
- 694 Schmidt LG, Dufeu P, Heinz A, Kuhn S, Rommelspacher H (1997) Serotonergic dysfunction  
695 in addiction: effects of alcohol, cigarette smoking and heroin on platelet 5-HT content.  
696 *Psychiatry Res* 72: 177-185
- 697 Stein M, Herman D, Conti M, Anderson B, Bailey G (2020) Initiating buprenorphine  
698 treatment for opioid use disorder during short-term in-patient 'detoxification': a randomized  
699 clinical trial. *Addiction* 115: 82-94
- 700 Stuendl A, Kunadt M, Kruse N, Bartels C, Moebius W, Danzer KM, Mollenhauer B,  
701 Schneider A (2016) Induction of alpha-synuclein aggregate formation by CSF exosomes  
702 from patients with Parkinson's disease and dementia with Lewy bodies. *Brain* 139: 481-494
- 703 The State Council China, 2019. 2018 China Drug Situation Report.
- 704 Timko C, Below M, Vittorio L, Taylor E, Chang G, Lash S, Festin FED, Brief D (2019)  
705 Randomized controlled trial of enhanced telephone monitoring with detoxification patients:  
706 3- and 6-month outcomes. *J Subst Abuse Treat* 99: 24-31
- 707 Tomkins DM, Sellers EM (2001) Addiction and the brain: the role of neurotransmitters in the  
708 cause and treatment of drug dependence. *CMAJ* 164: 817-821
- 709 Tseng AM, Chung DD, Pinson MR, Salem NA, Eaves SE, Miranda RC (2019) Ethanol  
710 Exposure Increases miR-140 in Extracellular Vesicles: Implications for Fetal Neural Stem  
711 Cell Proliferation and Maturation. *Alcohol Clin Exp Res* 43: 1414-1426
- 712 van Niel G, D'Angelo G, Raposo G (2018) Shedding light on the cell biology of extracellular  
713 vesicles. *Nat Rev Mol Cell Biol* 19: 213-228
- 714 Varga Z, Yuana Y, Grootemaat AE, van der Pol E, Gollwitzer C, Krumrey M, Nieuwland R  
715 (2014) Towards traceable size determination of extracellular vesicles. *J Extracell Vesicles* 3
- 716 Vidal R, Garcia-Marchena N, O'Shea E, Requena-Ocana N, Flores-Lopez M, Araos P,  
717 Serrano A, Suarez J, Rubio G, Rodriguez de Fonseca F *et al* (2020) Plasma tryptophan and  
718 kynurenine pathway metabolites in abstinent patients with alcohol use disorder and high  
719 prevalence of psychiatric comorbidity. *Prog Neuropsychopharmacol Biol Psychiatry* 102:  
720 109958
- 721 Volkow ND, Koob G, Baler R (2015) Biomarkers in substance use disorders. *ACS Chem*  
722 *Neurosci* 6: 522-525
- 723 Wang CC, Ortiz-Gonzalez XR, Yum SW, Gill SM, White A, Kelter E, Seaver LH, Lee S,  
724 Wiley G, Gaffney PM *et al* (2018) betaIV Spectrinopathies Cause Profound Intellectual  
725 Disability, Congenital Hypotonia, and Motor Axonal Neuropathy. *Am J Hum Genet* 102:  
726 1158-1168
- 727 Wang X, Sun L, Zhou Y, Su QJ, Li JL, Ye L, Liu MQ, Zhou W, Ho WZ (2019) Heroin  
728 Abuse and/or HIV Infection Dysregulate Plasma Exosomal miRNAs. *J Neuroimmune*  
729 *Pharmacol*
- 730 Zhang H, Liu J, Qu D, Wang L, Wong CM, Lau CW, Huang Y, Wang YF, Huang H, Xia Y  
731 *et al* (2018) Serum exosomes mediate delivery of arginase 1 as a novel mechanism for  
732 endothelial dysfunction in diabetes. *Proc Natl Acad Sci U S A* 115: E6927-E6936

733 Zhang Y, Pak C, Han Y, Ahlenius H, Zhang Z, Chanda S, Marro S, Patzke C, Acuna C, Covy  
734 J *et al* (2013) Rapid single-step induction of functional neurons from human pluripotent stem  
735 cells. *Neuron* 78: 785-798  
736 Zhao C, Huang C, Weng T, Xiao X, Ma H, Liu L (2012) Computational prediction of  
737 MicroRNAs targeting GABA receptors and experimental verification of miR-181, miR-216  
738 and miR-203 targets in GABA-A receptor. *BMC Res Notes* 5: 91  
739 Zhao LG, Wang J, Li J, Li QF (2020) miR-744-5p inhibits cellular proliferation and invasion  
740 via targeting ARF1 in epithelial ovarian cancer. *Kaohsiung J Med Sci* 36: 799-807  
741 Zheng T, Liu L, Aa J, Wang G, Cao B, Li M, Shi J, Wang X, Zhao C, Gu R *et al* (2013)  
742 Metabolic phenotype of rats exposed to heroin and potential markers of heroin abuse. *Drug*  
743 *Alcohol Depend* 127: 177-186  
744

745 **Figure legends**

746 **Figure 1: Pipeline showing the experimental design in this study.** (A-C) An overview of the  
747 experimental design. (D-E) Characterisation of exosomes derived from the plasma of Substance use  
748 disorder (SUD) patients and controls; (D) The shape and structure of plasma exosomes isolated by  
749 ultracentrifugation under transmission electron microscopy (TEM); (E) The size of exosomes was  
750 analysed by nanoparticle tracking analysis (NTA); (F) Western blots of exosomal membrane markers,  
751 including Alix, CD63, and CD81. The exosomes isolated from each participant underwent both TEM,  
752 NTA and Western blotting to confirm successful enrichment and ensure limited contamination with  
753 cellular debris prior to small RNA deep sequencing.

754

755 **Figure 2: Distinct exosomal miRNAs in HC, HDPs and MDPs.** Small RNA sequencing was  
756 performed to reveal the small RNA content in plasma samples collected from HC and patients with  
757 SUDs. (A-D) Statistically significant (Fold change  $\leq -1.5$  and  $\geq 1.5$ ,  $p.fdr \leq 0.05$ ) tRNA fragments  
758 were detected in (A, B) HDPs vs HC and (C, D) MDPs vs HC. (E) Venn diagram showing the number  
759 of the DE-miRNAs identified in HDPs and MDPs compared to HC. (F, G) Predicted functional  
760 pathways and biological functions (F) associated with mRNA targets of the 20 overlapped DE-  
761 miRNAs and (G) miRNA-mRNA interacting network. (H) ROC AUC for the diagnosis of patients  
762 with SUDs compared to HC. (I) Expression of miR-451a in HC, HDPs and MDPs. (J) ROC AUC for  
763 the diagnosis of MDPs compared to HDPs. (K) Expression of miR-21 in HC, HDPs and MDPs. The  
764 range of expression values in the groups is indicated by the error bars.

765

766 **Figure 3: WGCNA of plasma exosome samples uncovered dynamic changes of miRNA**  
767 **signatures during substance withdrawal.** (A) Hierarchical cluster dendrogram using WGCNA  
768 analyzing miRNA sequencing data. A total of 8 modules were identified after 0.25 threshold merging.  
769 (B) Module trait correlation analysis revealed that several key modules were significantly correlated  
770 with substance use and/or different withdrawal stages. (C, E, G, I, K, M) Eigengene expression of six  
771 selected modules across 4 groups of samples. Color code of the modules is preserved. (D, F, H, J, L,  
772 N) Expression patterns of key miRNAs representing six selected modules across subgroups of HDPs  
773 and MDPs.

774

775 **Figure 4: Effects of hsa-miR-744-5p on neurite outgrowth in human iPSC derived neurons.** (A)  
776 Flow diagram of human iPSC derived neuron cell generation. (B) Representative differential  
777 interference contrast (DIC), MAP2 (Red) and TUJ1 (Green) fluorescence images illustrating the  
778 generation of human iPSC derived neurons cell. (C) Representative images illustrating the effects of  
779 hsa-miR-744-5p or control in neurite outgrowth assay on Day3, Day5 and Day7. (D-F) Statistics of  
780 neurite outgrowth assay after induction of hsa-miR-744-5p expression in human iPSC derived

781 neurons. All data are presented as mean  $\pm$  SD;  $n \geq 3$ .  $p < 0.05$ , one-way ANOVA with Bonferroni  
782 post hoc analysis.  
783

A

## Discovery cohort (n = 70)

Heroin dependent patients (n = 30)


Healthy controls  
(n = 10)

Methamphetamine dependent patients (n = 30)

7-day  
withdrawal3-month  
withdrawal12-month  
withdrawal

## Validation cohort (n = 70)


Heroin dependent patients (n = 30)

Healthy controls  
(n = 10)

Methamphetamine dependent patients (n = 30)

7-day  
withdrawal3-month  
withdrawal12-month  
withdrawal

B



Sample collection




Sample preparation



UPLC-MS/MS

MS/MS  
Data analysis


C

Ultrafiltration &  
Size exclusion chromatographyTransmission electron  
microscopy


High-throughput sequencing

Sequencing  
Data analysis


D










E







F






Heroin vs Control Methamphetamine vs Control




A

## Cluster Dendrogram




B



## Module-trait relationships




C





D




E





F




G





H




I





J




K





L














M



N





**FAM57B** Family with sequence similarity 57 member B  
**FDX1L** Ferredoxin 1-like  
**PPP5C** Protein phosphatase 5 catalytic subunit  
**PSENEN** Presenilin Enhancer, Gamma-Secretase Subunit  
**SPTBN4** Spectrin beta, non-erythrocytic 4  
**VPS37D** VPS37D Subunit Of ESCRT-I

**Table 1: Clinical and Demographic characteristics of study participants.**

	<i>Discovery cohort</i>			<i>Validation cohort</i>			<i>Discovery.p</i>	<i>Validation.p</i>	<i>Discovery.p</i>	<i>Validation.p</i>	<i>Discovery.p</i>	<i>Validation.p</i>
	Control (n=10)	Heroin (n=30)	Methamphetamine (n=30)	Control (n=10)	Heroin (n=30)	Methamphetamine (n=30)	Control vs Heroin	Control vs Methamphetamine	Control vs Methamphetamine	Heroin vs Methamphetamine	Heroin vs Methamphetamine	Heroin vs Methamphetamine
<b>Age (year)</b>	36.71±7.32	37.25±7.59	36.58±7.72	36.03±9.05	36.84±8.27	36.28±8.42	0.7667	0.7906	0.9875	0.9805	0.7117	0.6467
<b>BMI</b>	21.36±1.68	22.05±1.58	21.56±1.47	22.01±1.6	21.38±1.89	21.58±1.28	0.3903	0.3408	0.9378	0.5739	0.3042	0.5106
<b>History (year)</b>	NA	7.8±2.52	7.46±2.78	NA	6.79±2.97	7.06±2.51	NA	NA	NA	NA	0.2976	0.6467
<b>Education*</b>	1/6/2/1	9/12/7/2	9/11/9/1	1/4/4/1	6/10/9/5	7/9/9/5	0.5682	0.8801	0.3203	0.8460	0.9184	1.0000
<b>Income**</b>	0/3/4/3/0	5/12/7/4/2	5/11/5/7/2	0/4/4/2/0	5/12/8/4/1	5/11/5/7/2	0.4330	0.7015	0.4111	0.4595	0.9083	0.7684
<b>HAM-A</b>	4.9±2.42	12.25±5.86	11.3±5.1	5.4±2.17	14.35±3.66	13.55±4.58	<b>0.0005</b>	<b>0.0000</b>	<b>0.0014</b>	<b>0.0001</b>	0.7245	0.6935
<b>HAM-D</b>	8.2±3.82	12.95±5.89	13.45±5.99	8.8±3.05	13.15±6.72	13.8±5.68	<b>0.0134</b>	0.1708	<b>0.0170</b>	<b>0.0273</b>	0.7140	0.8283

Data are mean ± SD. Group differences are evaluated with Kruskal's test for continuous variables and fisher's test for categorical variables. \* Education levels: illiteracy/primary school/middle school/college; \*\* Income levels: monthly 0~1000¥/1000~3000¥/3000~5000¥/5000~10000¥/10000+¥. HAM-A: Hamilton Rating Scale for Anxiety; HAM-D: Hamilton Depression Rating Scale.

**Table 2 Detailed information of the 7 neurotransmitters isolated from peripheral blood plasma of HC, HDPs and MDPs from the discovery cohort.**

Metabolites	<i>mean</i>	<i>mean</i>	<i>mean</i>	<i>p</i>	<i>fdr.p</i>	<i>p</i>	<i>fdr.p</i>	<i>p</i>	<i>fdr.p</i>
	Control (n=10)	Heroin (n=30)	Methamphetamine (n=30)	Control vs Heroin		Control vs Methamphetamine		Heroin vs Methamphetamine	
<b>Choline</b>	3741.63± 1408.82	2335.26±972.98	2395.46±1192.87	<b>0.0127*</b>	<b>0.0260*</b>	<b>0.0173*</b>	<b>0.0260*</b>	0.8352	0.8352
<b>GABA</b>	30.53 ± 7.51	19.73±9.70	17.81±7.20	<b>0.0017*</b>	<b>0.0026*</b>	<b>0.0003*</b>	<b>0.0009*</b>	0.4028	0.4028
<b>Glutamic acid</b>	43307.29 ± 16338.27	31349.56±10167.58	36624.70±15934.20	0.0516	0.1549	0.1744	0.2617	0.3057	0.3057
<b>Glutamine</b>	8414.58 ± 2173.78	7771.86±1693.76	8089.17±1192.05	0.4119	0.6012	0.6012	0.6012	0.4189	0.6012
<b>Kynurenine</b>	1406.28 ± 328.97	1397.10±322.75	1464.27±239.13	0.7567	0.7567	0.2195	0.5664	0.3776	0.5664
<b>Serotonin</b>	44.7 1± 44.32	240.15±266.50	251.18±388.72	<b>4.8255E-5*</b>	<b>0.0001*</b>	<b>0.0009*</b>	<b>0.0013*</b>	0.5955	0.5955
<b>Tryptophan</b>	24923.06 ± 5255.84	21501.42±4011.26	22417.54±4106.69	0.0838	0.2514	0.1938	0.2907	0.3979	0.3979

**Table 3 Detailed information of the 7 neurotransmitters isolated from peripheral blood plasma in HDPs and MDPs across three withdrawal stages compared to HC.**

Metabolites	<i>mean</i>	<i>mean Heroin subgroup</i>			<i>p</i>	<i>fdr.p</i>										
	Control (n=10)	T1 (n=10)	T2 (n=10)	T3 (n=10)	Control vs T1	Control vs T2	Control vs T3	T1 vs T2	T2 vs T3	T1 vs T3						
<b>Choline</b>	3741.63± 1408.82	2626.56±832.41	1502.44±742.8	2822.63±831.48	0.055	0.0825	<b>0.0013*</b>	<b>0.0076*</b>	0.2413	0.2896	<b>0.0081*</b>	<b>0.0161*</b>	<b>0.0037*</b>	<b>0.0112*</b>	0.6534	0.6534
<b>GABA</b>	30.53 ± 7.51	22.87±9.4	10.96±5.19	24.79±8.05	<b>0.045*</b>	0.0680	<b>0.0004*</b>	<b>0.0023*</b>	0.0756	0.0907	<b>0.0047*</b>	<b>0.0094*</b>	<b>0.0014*</b>	<b>0.0043*</b>	0.6534	0.6534
<b>Glutamic acid</b>	43307.29 ± 16338.27	32234.53±10686.18	31673.31±8813.79	30261.7±11720.86	0.1309	0.3061	0.1530	0.3061	0.0452	0.2709	0.7911	0.7911	0.5956	0.7841	0.6534	0.7841
<b>Glutamine</b>	8414.58 ± 2173.78	6317.54±1519.38	8525.5±1527.58	8402.46±1164.21	<b>0.0373*</b>	0.0747	0.7133	0.8560	1.0000	1.0000	0.0171	0.0514	0.7133	0.8560	<b>0.0080*</b>	<b>0.0478*</b>
<b>Kynurenine</b>	1406.28 ± 328.97	1419.92±426.95	1236.32±284.78	1521.44±186.48	0.8383	0.8383	0.2703	0.5407	0.1212	0.3637	0.3772	0.5658	<b>0.0160*</b>	0.0961	0.5403	0.6483
<b>Serotonin</b>	44.7 1± 44.32	484.34±351.69	141.53±98.29	109.13±78.16	<b>0.0005*</b>	<b>0.0031*</b>	<b>0.0048*</b>	<b>0.0097*</b>	<b>0.0091*</b>	<b>0.0125*</b>	<b>0.0100*</b>	<b>0.0125*</b>	0.4877	0.4877	<b>0.0022*</b>	<b>0.0066*</b>
<b>Tryptophan</b>	24923.06 ± 5255.84	20175±3341.1	20521.81±4946.83	23576.84±3015.11	0.055	0.1412	0.0942	0.1412	0.6776	0.8131	0.8598	0.8598	0.0791	0.1412	<b>0.0373*</b>	0.1412

Metabolites	<i>mean</i>	<i>mean Methamphetamine subgroup</i>			<i>p</i>	<i>fdr.p</i>										
	Control (n=10)	T1 (n=10)	T2 (n=10)	T3 (n=10)	Control vs T1	Control vs T2	Control vs T3	T1 vs T2	T2 vs T3	T1 vs T3						
<b>Choline</b>	3741.63± 1408.82	2834.48±1284.93	1597.76±889.53	2798.04±1043.17	0.0942	0.1412	<b>0.0013*</b>	<b>0.0079*</b>	0.1859	0.2231	<b>0.0200*</b>	<b>0.0399*</b>	<b>0.0173*</b>	<b>0.0399*</b>	0.7133	0.7133
<b>GABA</b>	30.53 ± 7.51	19.01±3.82	10.61±5.15	23.93±4.59	<b>0.0022*</b>	<b>0.0033*</b>	<b>0.0002*</b>	<b>0.0010*</b>	<b>0.0411*</b>	<b>0.0411*</b>	<b>0.0022*</b>	<b>0.0033*</b>	<b>0.0003*</b>	<b>0.0010*</b>	<b>0.0335*</b>	<b>0.0401*</b>
<b>Glutamic acid</b>	43307.29 ± 16338.27	40629.08±21910.23	37363.75±12385.88	32281.72±13121.73	0.4379	0.5255	0.3847	0.5255	0.1212	0.5255	0.7133	0.7133	0.3847	0.5255	0.2703	0.5255
<b>Glutamine</b>	8414.58 ± 2173.78	7586.42±1038.01	8094.06±1044.53	8536.76±1377.19	0.3074	0.6849	0.5708	0.6849	0.7913	0.7913	0.3913	0.6849	0.4727	0.6849	0.1309	0.6849
<b>Kynurenine</b>	1406.28 ± 328.97	1461.27±213.39	1477.66±320.55	1453.59±185.31	0.4379	0.8759	0.4274	0.8759	0.1859	0.8759	0.9674	0.9674	0.7913	0.9674	0.9674	0.9674
<b>Serotonin</b>	44.7 1± 44.32	332.40±271.43	344.78±595.65	84.49±51	<b>0.0017*</b>	<b>0.0100*</b>	<b>0.0113*</b>	<b>0.0340*</b>	0.0539	0.0809	0.3477	0.3477	0.1620	0.1944	<b>0.0247*</b>	<b>0.0495*</b>
<b>Tryptophan</b>	24923.06 ± 5255.84	20127.19±3391.17	22252.38±4774.18	24644.01±2944.41	<b>0.0373*</b>	0.1120	0.1859	0.3689	0.8501	0.8501	0.3074	0.3689	0.2730	0.3689	<b>0.0101*</b>	0.0607

**Table 4 Significant miRNAs that change in exosomes derived from both HDPs and MDPs.**

gene_id	Control vs Heroin			Control vs Methamphetamine		
	foldchange	<i>p</i>	<i>fdr.p</i>	foldchange	<i>p</i>	<i>fdr.p</i>
hsa-miR-375-3p	-1.82	2.76E-05	1.29E-03	-1.98	3.89E-05	3.20E-03
hsa-miR-484	-1.71	8.08E-06	6.36E-04	-1.58	4.06E-05	3.20E-03
hsa-miR-548b-5p	-1.52	2.56E-06	3.53E-04	-1.34	6.57E-06	1.81E-03
hsa-miR-451a	-1.52	2.51E-06	3.53E-04	-1.26	1.97E-05	2.81E-03
hsa-miR-363-3p	-1.47	6.15E-08	3.39E-05	-0.99	2.04E-05	2.81E-03
hsa-miR-548c-5p	-1.30	1.67E-05	1.15E-03	-1.11	1.16E-04	6.15E-03
hsa-miR-92b-3p	-1.32	7.59E-05	2.61E-03	-1.08	5.17E-04	0.017
hsa-miR-548d-5p	-1.18	7.86E-06	6.36E-04	-1.05	5.41E-07	2.98E-04
hsa-miR-1180-3p	-1.12	4.54E-05	1.79E-03	-0.98	1.81E-04	7.69E-03
hsa-miR-92a-3p	-1.09	4.68E-06	5.16E-04	-0.92	4.06E-05	3.20E-03
hsa-miR-486-5p	-0.98	2.07E-04	5.55E-03	-1.02	1.34E-04	6.15E-03
hsa-miR-576-5p	-1.23	1.78E-06	3.53E-04	-0.66	1.86E-03	0.035
hsa-miR-3150b-3p	-0.78	4.43E-03	0.048	-0.87	1.82E-03	0.035
hsa-miR-629-5p	-0.75	1.62E-03	0.025	-0.76	1.04E-03	0.027
hsa-miR-4732-3p	-0.64	2.70E-03	0.035	-0.86	1.34E-04	6.15E-03
hsa-miR-16-5p	-0.78	1.50E-04	4.87E-03	-0.67	7.29E-04	0.020
hsa-miR-4286	0.59	2.76E-03	0.035	0.69	5.28E-04	0.017
hsa-miR-151b	0.78	9.03E-04	0.017	0.73	1.49E-03	0.035
hsa-miR-151a-5p	0.81	3.62E-04	7.98E-03	0.75	6.71E-04	0.019
hsa-miR-744-5p	1.01	3.85E-04	8.16E-03	0.83	1.62E-03	0.035